statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation...

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) and Kezar Life Sciences (NASDAQ:KZR - Get Free Report) are both small-cap medical companies, but which is the superior business? We will...

Kezar Life Sciences (NASDAQ:KZR) vs. Centessa Pharmaceuticals (NASDAQ:CNTA) Head to Head Comparison

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for...

Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk...

Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of Chinas National Medical Products Administration (NMPA...

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Everest Medicines, Kezar Life Sciences get China IND approval for PALIZADE trial

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for...

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Volume	40,084.00
52-Wk High	$3.13
52-Wk Low	$0.6746

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.33	--	--	N/A
Q4'23	-$0.38	-$0.44	-15.93%	MISSED
Q3'23	-$0.36	-$0.32	10.23%	BEAT
Q2'23	-$0.32	-$0.34	-6.25%	MISSED
Q1'23	-$0.29	-$0.31	-8.14%	MISSED

KZR Kezar Life Sciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals